Download PDFPDF

Vasoproliferative tumours of the retina
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Intravitreal injection of crystalline cortisone in treatment of retinal vasoproliferative
    • , Ophthalmologist
    • Other Contributors:
      • Jost B. Jonas, Antje Soefker

    We would like to congratulate Heimann and colleagues for their study on 21 patients presenting with retinal vasoproliferative tumours treated by cryotherapy, brachytherapy or enucleation. We wonder whether an intravitreal injection of crystalline cortisone, as single procedure or in combination with the strategies described by the authors' study, may be an additional option in the therapeutic...

    Show More
    Conflict of Interest:
    None declared.